SUTIMLIMAB

UNII:	GNWE7KJ995
Formula:
Preferred Substance Name:	SUTIMLIMAB

2049079-64-1
BIVV009
BIVV-009
ENJAYMO
IMMUNOGLOBULIN G4, ANTI-(HUMAN COMPLEMENT C1S) (HUMANIZED MOUSE MONOCLONAL TNT009 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL TNT009 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS COMPLEMENT C1S SUBCOMPONENT (C1 ESTERASEEC=3.4.21.42)) HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-445) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*03 (90%) (IGHD)-IGHJ4*01) (8.8.11) (1-118)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(226)), CH2(L5>E(233)) (119-445)), (132-216')-DISULFIDE WITH .KAPPA. CHIMERIC LIGHT CHAIN (1'-216') (V-KAPPA (MUS MUSCULUS IGKV4-74*01 (83%)/HOMO SAPIENS IGKV3D-7*01 (78%) IGKJ2*01) (7.3.10) (1'-109')-HOMO SAPIENS IGKC*01 (110'-216')), DIMER (224-224'':227-227'')-BISDISULFIDE
SUTIMLIMAB [INN]
SUTIMLIMAB [JAN]
SUTIMLIMAB [USAN]
SUTIMLIMAB [WHO-DD]
SUTIMLIMAB JOME [WHO-DD]
SUTIMLIMAB-JOME
TNT009
TNT-009

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

SUTIMLIMAB

Synonyms and Mappings

Resources